In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

InSightec raises $150mm in Series E round prior to planned IPO

Executive Summary

In the largest late-stage round by an Israeli device company to date, InSightec Ltd. (magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS)) raised $150mm in a Series E round led by Koch Disruptive Technologies (an investment group of the diversified company Koch Industries), which was joined by InSightec's returning backers Elbit Imaging (which holds a 31.3% stake), York Capital, Exigent Capital Group, GE Healthcare, GEOC, and Meditech Advisors. The company will use the proceeds to advance commercialization efforts for its MRgFUS technologies, ExAblate and ExAblate Neuro, in approved indications in essential tremor, cancer pain, neuropathic pain, prostate cancer, and uterine fibroids, and continue R&D in new areas, including Alzheimer's disease, Parkinson’s disease, obsessive-compulsive disorder, and brain, liver, and pancreatic cancers. Industry sources say this is the InSightec's last private round before a planned IPO.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
      • Ultrasound
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies